New Guidelines: Interpretation, Application and the Future

Hershey, Andrew D.; Oskoui, Maryam; Pringsheim, Tamara; Holler-Managan, Yolanda; Potrebic, Sonja; Billinghurst, Lori; Gloss, David; Licking, Nicole; Sowell, Michael; Victorio, M. Cristina; Gersz, Elaine M.; Vrijsen, Emily; Zanitsch, Heather; Yonker, Marcy; Mack, Kenneth J.; Gelfand, Amy A.; Szperka, Christina L.; Powers, Scott W.

doi:10.1111/head.13629

Cited by 2 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 5 , 6 , 7 , 8 , 9 For people ages 15 to 49 years, migraine is the top cause of years lived with disability. 10 , 11 Because there are few rigorous pediatric trials, 12 , 13 clinical care for youth with migraine is primarily based on expert opinion and extrapolation of adult medication trial data. 11 , 14 , 15 The dearth of evidence for pediatric patients motivated the Childhood and Adolescent Migraine Prevention (CHAMP) trial ( NCT01581281 ), 16 a multicenter study funded by the National Institutes of Health.…”

Section: Introductionmentioning

confidence: 99%

“… 10 , 11 Because there are few rigorous pediatric trials, 12 , 13 clinical care for youth with migraine is primarily based on expert opinion and extrapolation of adult medication trial data. 11 , 14 , 15 The dearth of evidence for pediatric patients motivated the Childhood and Adolescent Migraine Prevention (CHAMP) trial ( NCT01581281 ), 16 a multicenter study funded by the National Institutes of Health. The CHAMP trial compared the 2 most commonly used medications in current practice, amitriptyline 17 and topiramate, 12 , 18 , 19 with a placebo and with each other.…”

Section: Introductionmentioning

confidence: 99%

“…It is the second most disabling disease in the world, yet it is underrecognized, undertreated, and underappreciated . For people ages 15 to 49 years, migraine is the top cause of years lived with disability . Because there are few rigorous pediatric trials, clinical care for youth with migraine is primarily based on expert opinion and extrapolation of adult medication trial data .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of Headache Days and Disability 3 Years After Participation in the Childhood and Adolescent Migraine Prevention Medication Trial

et al. 2021

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Migraine is a common neurological disease that often begins in childhood and continues into adulthood; approximately 6 million children and adolescents in the United States cope with migraine, and many frequently experience significant disability and multiple headache days per week. Although pharmacological preventive treatments have been shown to offer some benefit to youth with migraine, additional research is needed to understand whether and how these benefits are sustained.OBJECTIVE To survey clinical status of youth with migraine who participated in the 24-week Childhood and Adolescent Migraine Prevention (CHAMP) trial over a 3-year follow-up period.

show abstract